Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

A four-month FDA delay prompted a cash-strapped biotech company to shutter. The White House’s proposed NIH cuts are drawing ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...

What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

Anthropic (ANTHRO) has acquired Coefficient Bio, a biotech focused on developing AI models for biological research, for slightly more than $400M, according to The Information and a report from Eric ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...